| 📌 The essentials On April 10, 2026, the FDA issued a Complete Response Letter (CRL) to Replimune for BLA 125827, its application for vusolimogene oderparepvec (RP1, also known as Vusolimogene oderparepvec, brand name RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on prior PD-1-based therapy. The CRL is not a final rejection. It identifies deficiencies Replimune must address before the application can be reconsidered. The FDA’s concerns are entirely evidentiary, not about safety. The core problem: the pivotal evidence came from a single-arm Phase 2 study (RPL-001-16), which the FDA had previously told Replimune was insufficient to support approval. Without a randomized comparator, the agency could not determine whether observed tumor responses were attributable to RP1, to nivolumab, or to patient-specific factors. The path forward: the FDA requires adequate and well-controlled randomized trials demonstrating RP1’s independent contribution to clinical benefit. Replimune may request a Type A meeting with the FDA to discuss whether modifications to the ongoing IGNYTE-3 Phase 3 trial (NCT05765994) could address the requirements. |
|---|
Unresectable melanoma that has progressed after checkpoint inhibitor therapy is one of the hardest clinical scenarios in oncology. PD-1 inhibitors like pembrolizumab and nivolumab transformed the treatment of metastatic melanoma beginning in 2014, extending survival for patients who previously had very limited options. But when melanoma progresses on those drugs, the question of what comes next has no clear answer. The approved options are limited, the responses are modest, and the disease is often aggressive by the time it reaches that stage.
Vusolimogene oderparepvec (RP1) is an oncolytic herpes simplex virus, an engineered virus designed to selectively infect and kill tumor cells while simultaneously triggering a systemic immune response. It was specifically developed to work in combination with checkpoint inhibitors and showed promising results in early-phase testing. Replimune submitted a Biologics License Application (BLA) based on Phase 2 data in combination with nivolumab.
On April 10, 2026, the FDA responded with a Complete Response Letter. The decision does not close the door on RP1. It identifies, in specific and instructive detail, exactly what the clinical evidence package was missing and what is required to proceed.
What Oncolytic Immunotherapy Is and Why RP1 Is Interesting
To understand what Replimune was trying to do, and why the regulatory challenge is real rather than arbitrary, it helps to understand the mechanism of oncolytic virotherapy.
Oncolytic viruses are engineered to selectively replicate inside tumor cells, causing them to burst and die, while largely sparing normal tissue. The death of those tumor cells releases antigens and danger signals that can alert the immune system to the presence of cancer. In theory, an oncolytic virus can convert a “cold” tumor, one with low immune infiltration and low response to checkpoint inhibitors, into a “hot” one where the immune system actively attacks the cancer.
RP1 is engineered from herpes simplex virus type 1 (HSV-1) with two modifications designed to enhance its therapeutic profile: deletion of the ICP34.5 gene to reduce neurovirulence and enhance tumor selectivity, and insertion of a GALV-GP R(-) fusogenic membrane glycoprotein that causes infected cells to fuse with neighboring cells, amplifying tumor cell death and antigen release. This fusogenic enhancement is what distinguishes RP1 from talimogene laherparepvec (T-VEC, Imlygic), the only previously approved oncolytic virus for melanoma, which does not carry this feature.
RP1 is administered by direct injection into tumor lesions (intratumoral injection). The proposed mechanism of clinical benefit involves both local tumor destruction at injected lesions and systemic immune activation that could, in principle, attack non-injected lesions and metastatic sites. That systemic effect is the central clinical and regulatory question: does injecting a virus into accessible tumors produce meaningful benefit throughout the body, and can a clinical trial reliably detect and attribute that benefit?
What the RPL-001-16 Trial Showed and Why It Was Not Enough
The pivotal evidence for the BLA came from RPL-001-16 (NCT03767348), a Phase 2 single-arm study evaluating RP1 plus nivolumab in patients with advanced cutaneous melanoma. The trial enrolled patients whose disease had progressed on prior PD-1 therapy, exactly the patient population with the highest unmet need in this disease.
In the Phase 2 data, the combination showed an objective response rate that generated initial enthusiasm in the oncology community. However, the FDA’s concern was not primarily about the magnitude of the responses. It was about whether the study design allowed any reliable conclusion about what caused them.
The FDA had communicated to Replimune prior to BLA submission that a single-arm trial in this combination setting was insufficient to demonstrate RP1’s contribution to clinical benefit. Replimune proceeded with the BLA nonetheless, apparently believing the strength of the data could overcome the design limitation.
It could not.
Why the FDA Issued the CRL: Four Specific Problems
1. The study design could not isolate RP1’s contribution
The fundamental problem with a single-arm trial combining RP1 with nivolumab is that nivolumab has established activity in melanoma. When a trial shows responses in patients receiving a known-active drug plus a new drug, with no control arm receiving the known-active drug alone, it is impossible to determine how much of the response came from the new drug. The FDA had been explicit that this design flaw was fatal to the application before it was submitted. A randomized trial comparing RP1 plus nivolumab versus nivolumab alone would allow direct attribution of incremental benefit to RP1.
2. The study population was too heterogeneous
Patients enrolled in RPL-001-16 varied substantially in prior treatments received, disease burden, lesion characteristics, and performance status. This variability made any cross-trial comparison unreliable and prevented meaningful benchmarking against external data. When a study is highly heterogeneous in ways not controlled by randomization, the results reflect the characteristics of who happened to be enrolled as much as the effects of the drug being studied.
3. Response assessments were uncertain and potentially confounded
The FDA identified multiple specific methodological issues that could artificially inflate the observed response rate:
Non-injected lesion problem: Many patients who showed an overall response did not have measurable non-injected target lesions. Since RP1 is injected directly into accessible tumors, any responses in those directly injected lesions could reflect local tumor destruction by the virus rather than systemic immune activation. If the drug’s value lies in producing systemic benefit beyond the injection site, the evidence needs to show response in tumors the drug never touched. In many cases, it could not.
Re-injection timing: Some patients received additional RP1 injections after new or enlarging lesions appeared. Under standard RECIST response criteria, new lesions or tumor enlargement typically counts as progression. Injecting the drug into new lesions and then observing their shrinkage can look like a response while obscuring what is actually a progressive disease pattern.
Surgical excisions and biopsies: Several patients underwent surgical removal or biopsy of lesions during the trial. These procedures can reduce measurable tumor burden in ways that are indistinguishable from drug-induced tumor shrinkage on imaging, inflating apparent response rates.
Local rather than central pathology review: Response assessments were performed by local investigators rather than a blinded central review committee. Local review is more susceptible to unconscious bias and inconsistency in applying response criteria than independent centralized review.
These factors collectively undermined the reliability of the reported objective response rate and duration of response as measures of true drug effect.
4. Supplemental data from the RP1-104 study were insufficient
Replimune attempted to support the BLA with additional data from an ongoing randomized Phase 2/3 study (RP1-104). However, the FDA found that only a small fraction of the planned study population had been treated at the time of submission, the data lacked independent review, the duration of response data were immature, and there was no prespecified statistical plan for the progression-free survival endpoint. The FDA concluded that these early, exploratory findings from RP1-104 could not compensate for the fundamental deficiencies in the pivotal RPL-001-16 study.
What the Field of Oncolytic Immunotherapy Needs to Learn From This
The RP1 CRL is instructive beyond Replimune specifically. It articulates the evidentiary standards the FDA will apply to intratumoral therapies combined with checkpoint inhibitors, and those standards were not invented for this application. They reflect well-established principles of clinical trial design.
Single-arm trials cannot isolate combination drug contributions. When a novel therapy is combined with an agent that already has proven activity in the indication, a randomized trial with an appropriate comparator arm is not optional. This principle applies across oncology, not just to oncolytic viruses.
Intratumoral therapies must demonstrate systemic activity. The clinical value proposition of an oncolytic virus is not that it kills directly injected tumors. Surgery can do that. The value proposition is that it triggers systemic immune responses that benefit the whole patient. Evidence of that systemic benefit requires trial designs that can detect and attribute responses in non-injected disease sites.
Methodological details matter enormously in solid tumor oncology. Re-injection timing, lesion selection for target measurement, the role of concurrent procedures, and the choice of central versus local review are not administrative details. They are scientifically material choices that determine whether a response rate number means what it appears to mean.
The FDA’s prior communications are not suggestions. Replimune knew before submitting its BLA that the agency had reservations about the single-arm design. Proceeding without addressing that concern was a high-risk regulatory strategy that did not succeed. The FDA’s pre-BLA communications and Type B meetings are the appropriate time to reach agreement on whether an evidentiary package is sufficient.
The Path Forward: IGNYTE-3
Replimune has an ongoing Phase 3 trial that may ultimately provide the evidence the FDA requires. The IGNYTE-3 trial (NCT05765994) is a randomized, controlled study designed specifically to address the gap identified in RPL-001-16. The FDA has indicated that Replimune may request a meeting to discuss whether modifications to IGNYTE-3 or additional studies could meet the requirements outlined in the CRL.
What that trial will need to show, based on the CRL’s specific feedback, is a clear, independently reviewed, randomized demonstration that the combination of RP1 plus nivolumab produces greater clinical benefit than nivolumab alone in patients with unresectable advanced melanoma that has progressed on prior PD-1 therapy. The primary endpoint will need to capture systemic activity, not just responses at injected sites, and the trial design will need to prevent the confounding issues that undermined RPL-001-16.
The timeline for such a result is measured in years, not months. Until IGNYTE-3 or another adequate study reports, RP1 remains investigational for this indication.
What This Means for Patients With Advanced Melanoma
For patients with unresectable melanoma that has progressed on PD-1 therapy, RP1 is not currently an approved treatment option. The CRL means it will remain investigational until adequate trial evidence is generated and reviewed.
The approved options for melanoma after progression on PD-1 therapy are limited and depend on individual patient factors including BRAF mutation status, prior treatment history, and performance status. Current options include:
- BRAF/MEK inhibitor combinations (dabrafenib plus trametinib, vemurafenib plus cobimetinib, encorafenib plus binimetinib) for patients with BRAF V600 mutations
- Ipilimumab (Yervoy) alone or in combination with nivolumab in appropriate patients
- Talimogene laherparepvec (T-VEC, Imlygic) for unresectable local or regional disease, the only currently approved oncolytic therapy in melanoma
- Clinical trial enrollment
For patients with unresectable advanced melanoma, especially those who have progressed on checkpoint inhibitor therapy, clinical trial enrollment is not a last resort. It is often the best option to access novel therapies in development. The IGNYTE-3 trial may have open enrollment sites. Additional clinical trial options can be searched at ClinicalTrials.gov.
The Melanoma Research Foundation and the Skin Cancer Foundation both maintain current information on melanoma treatment options and clinical trial resources.
For related coverage of how the FDA evaluates clinical evidence and what happens when that evidence is found insufficient, see our post on the camizestrant ODAC vote and what it reveals about ctDNA-guided treatment strategies and our analysis of pembrolizumab becoming the first approved immunotherapy for ovarian cancer to understand what a successful immunotherapy approval requires.
Sources
Complete Response Letter (primary source): CRL BLA125827 April 10, 2026. open.fda.gov.
Replimune press release: Replimune Announces Receipt of Complete Response Letter from FDA for RP1 (Vusolimogene Oderparepvec) BLA. Replimune. April 2026.
IGNYTE-3 Phase 3 trial: NCT05765994. ClinicalTrials.gov.
RPL-001-16 Phase 2 trial: NCT03767348. ClinicalTrials.gov.
Oncolytic virus immunotherapy review: Oncolytic Viruses: A New Class of Immunotherapy Agents. PMC8709598.
T-VEC FDA approval: FDA approves talimogene laherparepvec for melanoma. FDA.gov.
Nivolumab melanoma approval: FDA approves nivolumab for melanoma. FDA.gov.
RECIST criteria: New Response Evaluation Criteria in Solid Tumours (RECIST). PMC3107543.
PD-1 inhibitors overview: Checkpoint Inhibitors. StatPearls. NCBI.
Complete Response Letter explained: Complete Response Letter. FDA.gov.
NCCN melanoma guidelines: Melanoma Cutaneous: Clinical Practice Guidelines. NCCN.
BRAF inhibitors: BRAF Inhibitors. cancer.gov.
Melanoma cancer overview: Advanced Melanoma Treatment. American Cancer Society.
Patient resources: Melanoma Research Foundation | Skin Cancer Foundation | ClinicalTrials.gov: melanoma oncolytic
| Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. RP1 (vusolimogene oderparepvec) is not currently FDA-approved for any indication. Treatment decisions for advanced or metastatic melanoma should be made in consultation with a qualified oncologist experienced in melanoma and immunotherapy. |
|---|